在癌症的背景下GLP-1受体激动剂:未来的道路
1Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Science, Little Rock, Arkansas, United States.
American journal of physiology. Cell physiology
|April 26, 2025
概括
葡萄糖类-1受体激动剂 (GLP-1RAs) 越来越多地用于糖尿病和减肥,影响癌症代谢. 需要进一步的研究,以了解它们对癌症治疗和缓冲症的影响.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 代谢过程中的代谢.
背景情况:
- 类似葡萄糖类-1受体激动剂 (GLP-1RAs) 广泛用于2型糖尿病和体重管理.
- 越来越多的癌症患者同时使用GLP-1RA,需要了解它们的相互作用.
- GLP-1RAs的深度代谢作用表明它对癌细胞代谢和患者生理学有重大影响.
研究的目的:
- 探索GLP-1RAs对癌症代谢和治疗的潜在影响.
- 对使用GLP-1RAs的患者糖尿病,癌症新陈代谢和缓冲症的现有文献进行审查.
- 讨论与GLP-1RA在癌症患者的使用相关的潜在益处,如新辅助效应,以及与GLP-1RA在癌症患者使用相关的风险,如肌肉质量损失.
主要方法:
- 对GLP-1RAs,癌症新陈代谢和缓冲症现有研究的文献综述.
- 对GLP-1RAs在一般生理和癌细胞中所影响的代谢途径的分析.
- 综合当前证据,预测GLP-1RAs与癌症治疗之间的界面.
主要成果:
- GLP-1RA严重影响患者的新陈代谢,对癌细胞代谢有可预测的影响.
- 新出现的证据表明GLP-1RAs在某些癌症患者亚群中可能具有新辅助作用.
- 人们对GLP-1RA诱导的体重减轻存在担忧,可能会加剧肌肉质量损失和缓冲症.
结论:
- GLP-1RAs在癌症患者的代谢环境中是一个重要的因素.
- 由于潜在的益处和风险,在癌症患者中需要仔细考虑GLP-1RA的使用.
- 进一步的研究至关重要,以阐明GLP-1RAs在癌症治疗和缓解症管理中的确切作用.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
8.8K
10:36In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
7.6K
相关概念视频
Glucagon-like Receptor Agonists
276
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
276
G Protein-coupled Receptors
10.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
10.9K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Oral Hypoglycemic Agents: Glinides
114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114
Dipeptidyl Peptidase 4 Inhibitors
142
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
142
